Latest Cholangiocarcinoma Stories
Patients with inflammatory bowel disease (IBD) and other gastrointestinal (GI) disorders may be exposed to significant doses of diagnostic radiation.
Scientists at Fred Hutchinson Cancer Research Center and the Translational Genomics Research Institute (TGen) have discovered a literal 'break through' in pancreatic cancer.
Researchers at the University of Rochester Medical Center’s James P. Wilmot Cancer Center have made significant strides in the study of a primary cancer of the liver– Intrahepatic Cholangiocarcinoma (IHCC), also called biliary tract cancer.
Investigators at the Massachusetts General Hospital (MGH) Cancer Center have identified a new genetic signature associated with bile duct cancer, a usually deadly tumor for which effective treatment currently is limited.
The human liver fluke Clonorchis sinensis affects more than 35 million people in South East Asia and 15 million in China.
Incidence rates of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) have increased in the U.S.
Scientists have confirmed that metabolic syndrome, a constellation of conditions that increases the risk of heart disease and diabetes, may also increase the risk of the two most common types of liver cancer.
Thalidomide has shown potential to be used as the first adjuvant therapy for hepatocellular carcinoma (HCC), according to data presented at the International Liver CongressTM 2011.
The Chinese liver fluke (Clonorchis sinensis) is a species of parasitic worm that is classified within the Platyhelminthes phylum. It can be found in Southeast Asia, Taiwan, Japan, and China and is present in nearly 30,000,000 humans today. It is thought to be one of the world’s most pervading parasites. The Chinese liver fluke requires two intermediate, or secondary, hosts and one definitive, or main, host to successfully complete its lifecycle. The first intermediate host is typically...
- totally perplexed and mixed up.